The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma

Rafael Contage Winter¹, Apio Claudio Martins Antunes², Francine Hehn de Oliveira¹

¹Neurosurgery Service, Hospital de Clínicas de Porto Alegre, Departments of ¹Neurosurgery and ²Neuropathology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
E-mail: ¹Rafael Contage Winter - rwinter@hcpa.edu.br; Apio claudio Martins antunes - aantunes@hcpa.edu.br; Francine Hehn de oliveira - fholiveira@hcpa.edu.br

ABSTRACT

Background: Meningioma is the most common benign intracranial neoplasm, accounting for 30% of all primary brain tumors. In 90% of cases, meningiomas are benign. Several aspects of molecular biology, including potential biomarkers, have been studied in attempts to better understand the natural history of meningiomas. Vascular endothelial growth factor (VEGF) is a biomarker responsible for inducing physiological and pathological angiogenesis. VEGF expression has been investigated as a potential predictor of several tumor aspects, including growth rate, recurrence rate, brain tissue invasion, peritumoral edema and surgical prognosis, and also as a marker of histological grade. However, there is no consensus in the literature with respect to the association between this biological factor and meningioma. We digitally analyzed immunohistochemical images using ImageJ software with the aim of correlating VEGF expression with tumor histology.

Methods: Tissue samples from patients presenting with meningioma who had undergone surgical removal between 2007 and 2016 at the Hospital de Clínicas de Porto Alegre (HCPA), in Southern Brazil, were analyzed to identify possible immunohistochemical associations between VEGF and histological grade and subtype.

Results: Seventy-six patients were included; 82% were female, mean age was 59.9 years (range: 18–91). No statistically significant associations were found between VEGF expression and histological grade or subtype (P = 0.310).

Conclusion: Our findings suggest that VEGF is frequently present in meningiomas regardless of histological grade and should not be used as a marker of severity or histological grade.

Keywords: Immunohistochemistry, Meningioma, Molecular biology, Vascular endothelial growth factor

INTRODUCTION

In 1922, Harvey Cushing coined the term meningioma to describe neoplasms arising from arachnoidal cells.¹⁴ Up to 90% of these tumors are benign. They are rarely found in children and incidence increases with age.¹⁵ In daily medical practice, they are often detected as incidental findings in imaging examinations performed for a wide range of diseases and indications.

Meningiomas can provoke a diverse set of symptoms, mainly depending on how they affect adjacent neurological structures, either by compression or irritation. Patients who are diagnosed with meningioma do not always need medical treatment. When indicated, the gold standard treatment is surgery, with total resection of the lesion including the involved dura (Simpson
Grade I resection). Notwithstanding, radiosurgery is thought to have a good tumor control rate for meningiomas of a certain size.

Several factors related to the molecular biology of meningiomas have been studied as potential biomarkers for growth rate, likelihood of recurrence, malignant transformation, and invasion of adjacent brain tissue. Despite the considerable number of studies examining these factors, results remain conflicting and inconclusive.\[1,3,5-12,14-22,30-32,34-37,38\]

One such biomarker is vascular endothelial growth factor (VEGF), a major inducer of physiological and pathological angiogenesis. Expression of VEGF in meningiomas is associated with peritumoral edema and leads to increased vascular permeability and microvessel density.\[10,13,18,27-29\] However, its relationships with recurrence rate, growth rate, and tumor grade remain controversial in the literature.

The present study aimed to determine the relationship between VEGF expression and tumor histology determined by digital analysis of immunohistochemical images using ImageJ software (NIH, USA).

MATERIALS AND METHODS

We analyzed tumor tissue samples from patients presenting with meningioma who had undergone surgery between 2007 and 2016 at the Hospital de Clínicas de Porto Alegre (HCPA), a university hospital in southern Brazil. Patients were included if they had not undergone preoperative embolization or been diagnosed with neurofibromatosis. The hospital's Research Ethics Committee approved this study under registration number 854.176 on October 28, 2014, and also waived the obligation to obtain informed consent from patients.

Hematoxylin and eosin (H and E)-stained slides were examined by a pathologist, and VEGF expression was analyzed immunohistochemically (ab1316, Abcam, USA, mouse monoclonal, clone VG-1, 1:2000 dilution). A BenchMark ULTRA automated platform was used to process samples (Ventana Medical Systems/Roche Diagnostics, USA), and ultraView Universal DAB Detection Kits were used to view reactions (Ventana Medical Systems/Roche Diagnostics, USA, catalogue no. 760-500).

Slides for immunohistochemical analysis were photographed under ×400 with an Olympus QColor5 camera (Olympus Corporation, Japan) coupled to an Olympus BX5 microscope (Olympus Corporation, Japan). The field photographed had been selected in advance by the pathologist. Images were digitally captured with QCapture software, version 2.81.0 (Quantitative Imaging Corporation, USA), using the same parameters for all slides and maintaining the same contrast settings for each sample. These images were digitally analyzed using ImageJ software, as described by Varghese, Bukhari, and Malhota, based on Ruifrok's study.\[31,36\]

Statistical analysis

The results of the immunohistochemical analysis of VEGF expression were compared to tumor grade and histological subtypes. The sample size of 76 specimens was calculated considering a difference of 30% VEGF expression in relation to tumor grade, to achieve statistical power of 80% and a 5% significance level. Proportions were compared using Pearson's Chi-square test or Fisher's exact test. Results were considered significant if $P < 0.05$, and SPSS software, version 21.0, was used for the analyses.

RESULTS

The study sample comprised 76 patients, representative of a typical population of patients with meningiomas with respect to age, sex, and histological grade. The mean age of patients was 59.9 (SD = 15.6) years. The youngest patient was 18 years old and the oldest was 91. There were 62 women and 14 men.

A total of 76 tumors were assessed; 67 were Grade I (88.2%), 4 were Grade II (5.3%), and 5 were Grade III (6.5%) [Table 1]. Histological subtypes are shown in [Table 2]. VEGF expression was positive in 49 tumors (64.5%) and negative in 27 tumors (35.5%). Regarding histological grade, there were no statistically significant differences in VEGF expression

| Grade | n  | %   |
|-------|----|-----|
| I     | 67 | 88.2|
| II    | 4  | 5.3 |
| III   | 5  | 6.6 |
| Total | 76 | 100 |

| Subtype                   | n  | (%)   | VEGF + (%) |
|---------------------------|----|-------|------------|
| Angiomatous               | 1  | 1.3   | 100        |
| Chordoid                  | 1  | 1.3   | 100        |
| Fibrous                   | 18 | 23.7  | 52.6       |
| Intraosseous              | 1  | 1.3   | 100        |
| Meningothelial            | 33 | 43.4  | 68.6       |
| Microcystic               | 2  | 2.6   | 50         |
| Papillary                 | 1  | 1.3   | 100        |
| Rhabdoid                  | 2  | 2.6   | 50         |
| Transitional              | 17 | 22.4  | 70         |
| Total                     | 76 | 100   | 64.5       |

VEGF: Vascular endothelial growth factor

| Table 1: Histological grades of the intracranial meningiomas in this sample. |
|----------------------------------|----|-----|
| Grade | n  | %   |
|-------|----|-----|
| I     | 67 | 88.2|
| II    | 4  | 5.3 |
| III   | 5  | 6.6 |
| Total | 76 | 100 |

| Table 2: Histological subtypes of the intracranial meningiomas in this sample. |
|----------------------------------|----|-------|------------|
| Subtype                   | n  | (%)   | VEGF + (%) |
|---------------------------|----|-------|------------|
| Angiomatous               | 1  | 1.3   | 100        |
| Chordoid                  | 1  | 1.3   | 100        |
| Fibrous                   | 18 | 23.7  | 52.6       |
| Intraosseous              | 1  | 1.3   | 100        |
| Meningothelial            | 33 | 43.4  | 68.6       |
| Microcystic               | 2  | 2.6   | 50         |
| Papillary                 | 1  | 1.3   | 100        |
| Rhabdoid                  | 2  | 2.6   | 50         |
| Transitional              | 17 | 22.4  | 70         |
| Total                     | 76 | 100   | 64.5       |
when Grades I, II, and III were compared ($P = 0.310$) [Table 3] or when low grade and high grade tumors were compared (Grade I vs. Grades II and III) ($P = 0.478$) [Table 4]. Certain epidemiological variables are listed in [Table 5], with the proportions of presence or absence of VEGF.

**DISCUSSION**

The natural history of meningioma is still unclear and course is unpredictable. Studies have employed molecular biology to search for factors that could be considered potential biomarkers of accelerated tumor growth rate, aggressive tumor behavior, and tumor grading and could, therefore, be used to guide more effective treatment in early stages and differential management of different tumor types.

New blood vessels develop to supply tumors through neoangiogenesis, which is a crucial process for tumor cell growth. Since VEGF is a major inducer of angiogenesis, VEGF expression is believed to be essential for tumor development.[1,9,11,21,30] For example, Ferrara and Davis-Smyth concluded that, in general, more aggressive tumors with higher grades and faster growth rates are associated with increased VEGF expression.[7]

Yamasaki et al. correlated VEGF expression with recurrence of Grade I meningioma after macroscopic total resection and found that high levels of VEGF expression were significantly associated with tumor recurrence, suggesting that this factor is one of the main predictors of recurrence.[38] Reszec et al. correlated expression of matrix metalloproteinase 9 (MMP-9) and VEGF in meningioma with peritumoral edema, and observed that VEGF was significantly associated with histological grade ($P = 0.001$).[29] In a cohort of 40 patients with meningioma, Sakuma et al. found that VEGF expression was related to development of peritumoral edema and to histological grade, thereby influencing the prognosis of patients.[32]

In contrast, and consistent with our findings, Baxter et al. prospectively assessed 175 patients and found no relationship between VEGF expression and histological meningioma grade.[3] This has also been described by other authors.[5,5,21,27,28] Pistolesi reported a potential relationship between specific VEGF isoforms and Grade I meningioma (isoform 189) and Grades II and III meningioma (isoforms 121 and 165), but found no statistically significant association between VEGF and histological grade.[28] Denizot et al. observed a relationship between VEGF and some histological subtypes in Grade I meningioma, but VEGF was not statistically associated with tumor grade.[9]

VEGF plays an important role in the neoangiogenesis of tumor cells, as demonstrated by several studies relating it...
to microvessel density in meningioma. However, the relationship between VEGF expression and meningioma remains unclear. Although some studies have related VEGF expression to peritumoral edema, the possible associations with histological subtypes and grades have not yet been well established.

We did not detect associations between VEGF expression and meningioma grade in our samples. Although VEGF is present in meningioma and is significantly involved in vascular development and central nervous system maintenance and repair, the effect most probably depends on other angiogenic factors.

CONCLUSION

VEGF and other factors of molecular biology have become essential to understanding the natural history of brain tumors, helping in the choice of appropriate treatment and follow-up decisions for patients presenting with meningioma. Our study suggests that there is no association between VEGF expression and meningioma grade. The limited sample size may be a contributing factor to the negative association and a very large sample size may be needed to detect associations. In view of the conflicting results reported in the literature, future studies with larger samples should focus on investigating the possible role of VEGF in tumor behavior.

Declaration of patient consent

Institutional Review Board (IRB) permission obtained for the study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Algire G. The Biology of Melanomas. New York: Academy of Sciences Press; 1947.
2. Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol 2011;28:99-106.
3. Baxter DS, Orrego A, Rosenfeld JV, Mathiesen T. An audit of immunohistochemical marker patterns in meningioma. J Clin Neurosci 2014;21:421-6.
4. Cushing H, Eisenhardt L. Meningiomas: Their Classification, Regional Behaviour, Life History, and Surgical End Results. Springfield, Illinois: Charles C. Thomas; 1938.
5. Denizot Y, de Armas R, Caire F, Moreau JJ, Pompeyepu I, Truffinet V, et al. The quantitative analysis of bFGF and VEGF by ELISA in human meningiomas. Mediators Inflamm 2006;2006:36376.
6. Dharmalingam P, Kumar VR, Verma SK. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol 2013;56:349-54.
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
8. Folkman J, Watson K, Ingbir D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
9. Folkman J, Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
10. Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997;40:1269-77.
11. Hai J, Li ST, Lin Q, Pan QG, Gao F, Ding MX. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery 2003;53:963-72.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
13. Hou J, Kshettry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in intracranial meningiomas: The emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus 2013;35:E2.
14. Jain RK, di Tomaso E, Duda DG, Loeffer JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
15. Jensen R, Lee J. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. Neurosurgery 2012;71:146-56.
16. Jensen RL. Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009;92:317-35.
17. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: A RANO review. Neuro Oncol 2014;16:829-40.
18. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E, et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 2013;56:349-54.
19. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000;46:938-48.
20. Lee SH, Lee YS, Hong YG, Kang CS. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. APMIS 2014;122:16-24.
21. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109-20.
22. Maiuri F, de Caro MB, Esposito F, Cappabianca P, Strazzullo V,
Pettinato G, et al. Recurrences of meningiomas: Predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007;82:63-8.

23. McDermott M, Meningiomas WC. In: Youmans J, editor. Neurological Surgery. Philadelphia, PA: WB Saunders; 1996. p. 2782-825.

24. Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: A review. Neurosurg Focus 2013;35:E18.

25. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000;50:1-15.

26. Pistolesi S, Boldrini L, Gisfredi S, de Ieso K, Camacci T, Caniglia M, et al. Angiogenesis in intracranial meningiomas: Immunohistochemical and molecular study. Neuropathol Appl Neurobiol 2004;30:118-25.

27. Pistolesi S, Fontanini G, Camacci T, de Ieso K, Boldrini L, Lupi G, et al. Meningioma-associated brain oedema: The role of angiogenic factors and pial blood supply. J Neurooncol 2002;60:159-64.

28. Platt SR. Angiogenesis and cerebral neoplasia. Vet Comp Oncol 2005;3:123-38.

29. Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L. Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int 2015;2015:646853.

30. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.

31. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-9.

32. Sakuma T, Nakagawa T, Ido K, Takeuchi H, Sato K, Kubota T. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J Neurooncol 2008;88:143-55.

33. Salokorpi N, Yrjänä S, Tuominen H, Karttunen A, Heljasvaara R, Pihlajaniemi T, et al. Expression of VEGF and collagen XVIII in meningiomas: Correlations with histopathological and MRI characteristics. Acta Neurochir (Wien) 2013;155:989-96.

34. Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C, Knop E. Vascular endothelial growth factor: The major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery 2010;67:1703-8.

35. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.

36. Varghese F, Bukhari AB, Malhotra R, Abhijit D. IHC profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 2014;9:e96801.

37. Vranic A, Popovic M, Cor A, Prestor B, Pizem J. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: A study of 86 patients. Neurosurgery 2010;67:1124-32.

38. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer 2000;89:1102-10.

How to cite this article: Winter RC, Antunes AC, de Oliveira FH. The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma. Surg Neurol Int 2020;11:328.